Lv1
40 积分 2023-11-13 加入
卡瑞利珠单抗致反应性皮肤毛细血管增生症临床诊治专家共识
8天前
已完结
Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial
14天前
已完结
Efficacy and safety of neoadjuvant SHR-A1811 with or without pyrotinib in women with locally advanced or early HER2-positive breast cancer: a randomized, open-label, phase II trial
15天前
已完结
Adjuvant Chemoradiation and Immunotherapy for Extrahepatic Cholangiocarcinoma and Gallbladder Cancer
26天前
已完结
Zanidatamab with and without Tislelizumab in HER2-Positive Gastroesophageal Cancer
26天前
已完结
Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial
26天前
已完结
Improved survival with immunotherapy for microsatellite unstable colorectal cancer with peritoneal metastases
29天前
已完结
Prior immunotherapy enhances survival outcomes of third‐line apatinib treatment in advanced gastric cancer: A retrospective cohort study
1个月前
已完结
Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): final report of a randomised, open-label, phase 3 trial
3个月前
已完结
Apatinib — new third-line option for refractory gastric or GEJ cancer
3个月前
已完结
皖公网安备34019202002308
